aldehyd
aketoamid
peptidyl
compound
antivir
b
r
c
enteroviru
emerg
pathogen
respons
mild
sever
respiratori
infect
occur
mostli
infant
children
teenag
one
nonpolio
enterovirus
acidlabil
biolog
similar
human
rhinovirus
hrv
origin
classifi
howev
approv
prevent
therapeut
measur
hrv
enterovirus
studi
evalu
antivir
activ
seri
dipeptidyl
compound
hrv
strain
demonstr
sever
peptidyl
aldehyd
aketoamid
peptidyl
compound
potent
inhibitor
hrv
strain
high
invitro
therapeut
indic
one
aketoamid
compound
shown
favor
pharmacokinet
profil
includ
favor
oral
bioavail
rat
recent
success
develop
aketoamid
proteas
inhibitor
hepat
c
viru
suggest
compound
may
high
potenti
optim
develop
emerg
well
hrv
enterovirus
belong
largest
genera
picornavirida
famili
one
genet
divers
medic
econom
import
virus
human
anim
pathogen
knowl
et
al
genu
enteroviru
divid
establish
propos
speci
among
least
speci
infect
human
includ
human
rhinoviru
hrv
aec
human
enterovirus
a
includ
enteroviru
coxsackieviru
b
cva
cvb
knowl
et
al
virus
enteroviru
genu
affect
million
peopl
worldwid
caus
wide
spectrum
diseas
asymptomat
mild
ill
sever
ill
tapparel
et
al
although
polioviru
pv
nearli
erad
immun
nonpolio
enterovirus
account
asept
mening
case
specif
viral
pathogen
identifi
connolli
hammer
sawyer
rotbart
origin
classifi
human
rhinoviru
hrv
first
identifi
california
biolog
similar
hrv
acidl
respiratori
track
target
tissu
enterovirus
schiebl
et
al
tokarz
et
al
caus
mild
sever
respiratori
ill
includ
fever
runni
nose
sneez
cough
bodymuscl
ach
wheez
difficulti
breath
age
infant
children
teenag
particularli
suscept
sever
symptom
infect
caus
particularli
sever
infect
children
asthma
exist
respiratori
ill
sinc
first
report
outbreak
occur
howev
sever
outbreak
report
last
year
europ
asia
north
america
especi
nationwid
outbreak
sever
respiratori
ill
due
infect
occur
us
ayscu
et
al
imamura
oshitani
messacar
et
al
midgley
et
al
tokarz
et
al
detect
specimen
patient
die
hrv
recent
reclassifi
enteroviru
genu
hrv
serotyp
one
commonli
implic
virus
common
cold
respons
case
arruda
et
al
makela
et
al
monto
hrv
also
import
agent
exacerb
preexist
respiratori
diseas
asthma
chronic
obstruct
pulmonari
diseas
kurai
et
al
genom
enterovirus
singlestrand
posit
sens
rna
molecul
consist
one
open
read
frame
orf
encod
polyprotein
orf
divid
three
consecut
region
process
region
yield
capsid
protein
process
region
yield
nonstructur
replic
protein
respect
fig
polyprotein
first
cleav
virusencod
proteas
junction
junction
site
cleav
gener
matur
nonstructur
structur
protein
fig
racaniello
chymotrypsinlik
cystein
also
constitu
replic
complex
help
evad
host
immun
interact
host
factor
chase
semler
function
structur
highli
conserv
among
enterovirus
attract
target
discoveri
antienteroviru
small
molecul
therapeut
lu
et
al
previous
synthes
peptidyl
inhibitor
base
conserv
key
featur
relat
proteas
encod
coronavirus
calicivirus
picornavirus
report
broadspectrum
antivir
activ
multipl
virus
enzymeor
cellbas
assay
system
studi
evalu
seri
dipeptidyl
compound
galas
kankanamalag
et
al
mandadapu
et
al
mandadapu
et
al
mandadapu
et
al
tiew
et
al
hrv
result
show
dipeptidyl
aketoamid
compound
potent
antivir
activ
well
multipl
strain
hrv
halfmaximum
concentr
ec
low
nanomolar
rang
aketoamid
compound
excel
vitro
safeti
indic
one
aketoamid
compound
test
rat
determin
favor
oral
bioavail
f
success
develop
aketoamid
proteas
inhibitor
hepat
c
viru
telaprevir
boceprevir
suggest
aketoamid
compound
may
high
potenti
drug
develop
emerg
well
hrv
seri
dipeptidyl
compound
synthes
report
elsewher
galas
kankanamalag
et
al
mandadapu
et
al
mandadapu
et
al
mandadapu
et
al
tiew
et
al
studi
five
pair
aldehyd
ketoamid
compound
focus
activ
hrv
strain
tabl
known
enteroviru
inhibitor
plecornail
entri
blocker
pevear
et
al
inhibitor
purchas
sigmaaldridg
st
loui
mo
human
embryon
lung
cell
hela
cell
maintain
minim
essenti
medium
mem
contain
obtain
atcc
manassa
va
virus
use
studi
hrv
strain
obtain
atcc
hyper
immun
guinea
pig
serum
rais
purchas
atcc
cdna
encod
full
length
gene
amplifi
rtpcr
previous
describ
anand
et
al
schultheiss
et
al
forward
primer
also
contain
start
codon
underlin
nucleotid
sequenc
encod
primer
aattgaattcaaggagatataccatgcatcatcatcatcatcat
ggaccagggttcgattttgcac
aattctcgagtcattgtgtatc
ggtaaagta
amplifi
product
subclon
vector
use
ecori
xhoi
enzym
site
express
purif
proteas
perform
standard
method
describ
previous
lab
takahashi
et
al
recombin
hrv
purchas
emd
chemic
inc
gibbstown
nj
fret
substrat
edansdfhlqgpdabcyl
synthes
anaspec
inc
fremont
ca
fret
proteas
assay
perform
follow
stock
solut
mm
substrat
compound
prepar
dmso
dilut
assay
buffer
assay
buffer
compris
mm
hepe
buffer
contain
nacl
mm
mm
edta
glycerol
mm
dtt
ph
proteas
mix
serial
dilut
compound
mock
dmso
ml
assay
buffer
incub
c
min
follow
addit
ml
substrat
fluoresc
read
obtain
fluoresc
micropl
reader
biotek
winooski
vt
use
excit
wavelength
nm
emiss
wavelength
nm
h
follow
addit
substrat
rel
fluoresc
unit
rfu
determin
subtract
background
valu
substrat
contain
well
without
proteas
raw
fluoresc
valu
describ
previous
takahashi
et
al
dosedepend
fret
inhibit
curv
fit
variabl
slope
use
graphpad
prism
softwar
version
san
diego
ca
order
determin
inhibitori
concentr
ic
compound
cell
line
use
cellbas
inhibit
assay
hrv
c
inhibitori
effect
compound
hrv
strain
also
test
hela
cell
c
confirm
result
obtain
cell
briefli
confluent
semiconflu
cell
inocul
viru
multipl
infect
moi
h
inoculum
replac
medium
contain
mockdmso
compound
mm
viru
infect
cell
incub
h
time
cell
show
cytopath
effect
viral
replic
determin
tissu
cultur
infecti
dose
tcid
assay
reed
muench
ec
valu
determin
use
graphpad
softwar
immunofluoresc
assay
ifa
also
perform
confirm
activ
one
aketoamid
compound
compound
cell
cell
inocul
mockmedium
moi
immedi
follow
addit
variou
concentr
mm
compound
mock
cell
fix
cold
methanol
h
postinfect
ifa
stain
primari
hyper
immun
guinea
pig
serum
rais
secondari
antibodi
fitc
conjug
goat
antiguinea
pig
serum
use
stain
cytotox
concentr
cc
compound
determin
replic
nonrepl
cell
trypsin
cell
confluent
cell
grown
plate
treat
variou
concentr
mm
compound
h
cytotox
measur
use
cytotox
nonradioact
cytotox
assay
kit
promega
madison
wi
crystal
violet
stain
vitro
therapeut
index
calcul
divid
cc
ec
enzym
select
compound
evalu
panel
repres
host
proteas
includ
human
neutrophil
elastas
hne
chymotrypsin
trypsin
thrombin
carboxypeptidas
di
fenza
et
al
grouta
et
al
sidhu
et
al
taggart
et
al
tanaka
et
al
previous
report
galas
kankanamalag
et
al
briefli
variou
concentr
mm
compound
test
proteas
ratio
proteas
percent
inhibit
index
enzym
select
determin
studi
perform
washington
biotech
inc
use
femal
spraguedawley
rat
iacuc
approv
protocol
washington
biotech
inc
three
healthi
specif
pathogen
free
spf
rat
given
oral
intraven
singl
dose
compound
mgkg
bodi
weight
drug
dissolv
ethanol
blood
collect
vacutain
tube
contain
edta
variou
time
point
h
plasma
obtain
centrifug
store
e
c
analysi
concentr
compound
plasma
measur
liquidliquid
extract
liquid
chromatographytandem
mass
spectrometri
lcmsm
method
tabl
structur
repres
depeptidyl
compound
use
studi
activ
ic
valu
indic
mean
standard
variat
two
three
separ
experi
e
e
e
washington
biotech
inc
drug
concentrationtim
graph
gener
graphpad
prism
softwar
data
fit
one
twocompart
model
without
lag
time
best
model
select
base
akaik
inform
criteria
use
pksolver
program
version
zhang
et
al
percent
bioavail
f
calcul
divid
po
plasma
auc
iv
plasma
auc
time
comparison
xray
crystal
structur
polioviru
crystal
structur
polioviru
bound
compound
pdb
previous
publish
group
superimpos
pdb
tan
et
al
base
sequenc
align
minim
root
mean
squar
rm
polioviru
use
pymol
pymol
molecular
graphic
system
version
oding
llc
kinet
compar
substrat
data
shown
aldehyd
aketomid
compound
tabl
highli
effect
ic
valu
rang
mm
assay
condit
compound
show
compar
activ
suggest
similar
structur
requir
inhibit
viral
proteas
tabl
dipeptidyl
compound
gln
surrog
posit
correspond
leucin
leu
phenylalanin
phe
cyclohexyl
alanin
cha
posit
tabl
compound
cha
compound
gener
activ
leu
phe
tabl
replac
hydrogen
ion
meta
posit
benzen
ring
chlorin
chang
howev
aketoamid
c
c
nh
cycprop
moieti
x
posit
increas
activ
compound
compar
correspond
aldehyd
cho
potent
compound
compound
ic
valu
compar
tabl
antivir
effect
compound
hrv
strain
cell
cultur
determin
human
embryon
lung
cell
line
cell
comparison
pleconaril
tabl
antivir
activ
compound
hrv
strain
hela
cell
c
compar
cell
data
shown
ec
valu
compound
gener
line
ic
valu
determin
proteas
assay
tabl
among
test
compound
aketoamid
compound
potent
activ
replic
virus
compound
also
show
similar
activ
compound
virus
cell
cultur
ec
valu
two
best
compound
compar
pleconaril
tabl
ifa
stain
cell
incub
variou
concentr
mm
compound
confirm
antivir
activ
compound
cell
fig
minim
nonspecif
stain
observ
ifa
stain
fig
cell
infect
treatment
compound
cytopath
effect
cpe
observ
cell
still
attach
plate
stain
viral
protein
fig
inhibit
viral
replic
increas
increas
concentr
compound
demonstr
cpe
viru
specif
stain
fig
e
list
compound
show
cytotox
mm
prolifer
nonprolifer
cell
sinc
offtarget
effect
host
proteas
potenti
caveat
drug
develop
select
profil
compound
determin
use
repres
panel
proteas
tabl
compound
determin
weak
inhibitor
hne
crossreact
toward
panel
host
enzym
indic
concentr
tabl
plasma
drug
concentr
data
fit
one
twocompart
model
without
lag
time
twoecompart
model
select
best
fit
lowest
akaik
inform
criteria
use
pksolver
program
version
zhang
et
al
plasma
concentrationtim
plot
compound
follow
iv
po
dose
shown
fig
summari
pk
paramet
follow
iv
po
administr
compound
list
tabl
iv
po
administr
compound
declin
rapid
initi
distribut
phase
follow
slower
elimin
phase
fig
iv
po
dose
concentr
compound
maintain
ec
valu
mm
h
less
h
fig
concentr
compound
also
remain
ec
valu
mm
mm
h
follow
iv
dose
howev
po
dose
rapidli
fell
ec
valu
less
one
hr
h
fig
oral
bioavail
f
compound
determin
indic
favor
oral
absorpt
superimpos
crystal
structur
polioviru
show
high
degre
similar
structur
fig
polioviru
rm
equival
residu
emerg
medicallyimport
enteroviru
recent
caus
sever
outbreak
associ
sever
respiratori
ill
us
mani
affect
labconfirm
case
children
underli
airway
diseas
asthma
suggest
mildli
symptomat
infect
like
much
preval
report
although
respiratori
ill
due
enteroviru
quit
common
among
children
adult
effort
made
develop
effect
treatment
medic
import
enterovirus
includ
licens
vaccin
drug
avail
except
polioviru
vaccin
yet
inhibitor
enteroviru
replic
broadli
classifi
three
main
group
inhibitor
attach
entri
andor
uncoat
replicas
inhibitor
proteas
inhibitor
chen
shih
chen
et
al
de
palma
et
al
liu
et
al
norder
et
al
tan
et
al
thibaut
et
al
replic
cycl
enteroviru
initi
attach
viru
particl
specif
receptor
host
cell
surfac
exampl
attach
inhibitor
includ
pleconaril
bind
hydrophob
pocket
within
enteroviru
major
capsid
protein
consequ
prevent
viral
attach
uncoat
recent
report
demonstr
pleconaril
also
inhibit
replic
bind
hydrophob
pocket
liu
et
al
pleconaril
fail
get
fda
approv
use
adult
potenti
advers
effect
sever
entri
inhibitor
pocapavir
vapendavir
evalu
efficaci
neonat
sepsi
associ
enteroviru
infect
http
inhibitor
replicas
rnadepend
rnapolymeras
inhibitor
report
viral
activ
use
target
inhibit
de
palma
et
al
design
enteroviru
inhibitor
primarili
util
known
peptidyl
recognit
element
variou
warhead
aldehyd
aketoamid
case
transitionst
analog
inhibitor
interact
activ
site
cystein
yield
tetrahedr
adduct
ramajayam
et
al
warhead
also
michael
acceptor
bunsatur
ester
vinyl
sulfon
contrast
aldehyd
aketoamid
react
activ
site
cystein
time
tabl
select
compound
import
host
proteas
includ
human
neutrophil
elastas
hne
chymotrypsin
trypsin
thrombin
carboxypeptidas
compound
incub
host
proteas
ration
percent
inhibit
determin
enzym
select
ie
compound
inhibit
f
mm
summari
pk
paramet
obtain
follow
intraven
iv
oral
po
dose
compound
mgkg
spf
rat
oral
intraven
given
singl
dose
compound
blood
collect
variou
time
point
plasma
drug
concentr
measur
data
fit
twocompart
model
use
pksolver
program
percent
bioavail
f
calcul
divid
po
plasma
auc
iv
plasma
auc
time
comparison
xray
crystal
structur
polioviru
yellow
bisulfit
adduct
compound
gray
pdb
red
polioviru
superimpos
use
pymol
imag
insert
show
hydrogen
bond
polioviru
compound
bisulfit
adduct
revert
back
aldehyd
compound
interact
form
complex
imag
also
show
hydrogen
bond
compound
enzym
conform
chang
enzym
bound
green
ligand
bound
form
magenta
interpret
refer
colour
figur
legend
reader
refer
web
version
articl
depend
manner
form
covalentlybound
enzymeinhibitor
adduct
kuo
et
al
matthew
et
al
patick
et
al
tan
et
al
extens
studi
inhibitor
class
michael
acceptor
variant
shown
activ
variou
enterovirus
includ
hrv
hung
et
al
matthew
et
al
patick
et
al
tan
et
al
howev
inhibitor
viral
proteas
yet
licens
enteroviru
infect
compound
use
studi
belong
seri
dipeptidyl
transit
state
inhibitor
seri
previous
report
activ
hrv
studi
conduct
structureact
relationship
studi
use
newli
gener
dipeptidyl
deriv
hrv
compar
rel
structur
requir
inhibit
determin
potenc
deriv
import
pathogen
compound
prototyp
dipeptidyl
aldehyd
previous
report
antihrv
activ
use
templat
structur
modif
new
deriv
base
enzym
cell
cultur
assay
signific
differ
activ
compound
hrv
suggest
structur
requir
blockag
similar
hrv
although
amino
acid
homolog
hrv
observ
may
explain
overal
structur
similar
hrv
strike
similar
topographi
activ
site
determin
xray
crystallograph
studi
lu
et
al
hrv
similar
substrat
specif
near
absolut
requir
gln
residu
hydrophob
residu
leu
phe
fig
structureact
relationship
studi
also
show
interchang
leu
phe
posit
lead
mark
chang
activ
hrv
howev
presenc
cha
posit
yield
better
activ
hrv
compar
leu
phe
activ
compound
chang
upon
replac
hydrogen
ion
mcl
cap
suggest
presenc
chlorin
atom
ion
meta
posit
contribut
bind
interact
hrv
previou
studi
metachlorin
substitu
found
significantli
improv
efficaci
compar
inhibitor
unsubstitut
phenyl
ring
calicivirus
enzym
cell
base
assay
galas
kankanamalag
et
al
interestingli
aketoamid
compound
consist
potent
aldehyd
counterpart
hrv
enzym
cellbas
assay
potent
compound
aketoamid
compound
cha
benzen
cap
without
mcl
compound
previous
report
aketoamid
compound
less
effect
aldehyd
counterpart
calicivirus
coronarvirus
tiew
et
al
previou
current
find
suggest
choic
warhead
give
better
fit
may
differ
among
differ
virus
encod
xray
crystallograph
studi
may
provid
structur
basi
find
report
cocrystal
polioviru
bisulfit
adduct
compound
kim
et
al
pdb
fig
show
highli
conserv
activ
site
structur
bound
compound
fig
gln
surrog
ring
leu
carboxybenzyl
ring
compound
fit
site
respect
cytotox
test
compound
minim
mm
cell
indic
good
safeti
margin
therapeut
indic
addit
compound
also
shown
good
enzym
select
basic
serin
trypsin
thrombin
metallo
carboxypeptidas
proteas
well
serin
proteas
achymotrypsin
human
neutrophil
elastas
tabl
compound
show
potent
antivir
activ
hrv
consequ
pharmacokinet
oral
bioavail
evalu
rat
unfavor
pharmacokinet
poor
oral
bioavail
one
major
challeng
drug
develop
exemplifi
unsuccess
develop
display
poor
aqueou
solubl
low
oral
bioavail
develop
nasal
spray
howev
develop
stop
phase
ii
clinic
trial
anoth
irrevers
inhibitor
compound
enter
clinic
trial
compound
found
highli
effect
hrv
strain
ec
nm
relat
enterovirus
importantli
oral
avail
patick
et
al
also
drop
phase
clinic
trial
compound
shown
favor
oral
bioavail
rat
f
plasma
drug
concentr
remain
higher
vitro
ec
valu
h
follow
oral
administr
use
simpl
formul
oral
bioavail
structurallysimilar
aldehyd
compound
also
determin
f
valu
aldehyd
markedli
lower
shorter
haltliv
rat
compar
compound
data
shown
therefor
aketoamid
warhead
may
contribut
improv
oral
bioavail
pk
dipeptidyl
compound
well
smaller
size
mw
dipeptidyl
compound
compar
bulkier
durat
compound
rat
plasma
ec
valu
follow
oral
dose
compound
mgkg
calcul
much
shorter
due
lower
antivir
activ
compound
compar
cell
cultur
repres
hrv
strain
minor
major
receptor
group
minor
hrv
serotyp
use
lowdens
lipoprotein
receptor
ldlr
major
hrv
serotyp
use
receptor
test
compound
major
group
hrv
strain
ec
ec
compar
data
shown
summari
new
deriv
compound
dipeptidyl
compound
seri
antihrv
activ
synthes
improv
inhibitori
activ
hrv
antivir
potenc
favor
pharmacokinet
properti
compound
suggest
compound
mayb
use
viabl
lead
candid
develop
andor
hrv
infect
singl
agent
combin
treatment
entri
inhibitor
